Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Monday

Brainstorm Cell Therapeutics (NASDAQ:BCLI) will likely be announcing its earnings results before the market opens on Monday, March 31st. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ:BCLI opened at $1.19 on Friday. The company’s fifty day moving average is $1.71 and its two-hundred day moving average is $2.03. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.25. The stock has a market capitalization of $6.79 million, a price-to-earnings ratio of -0.25 and a beta of 0.74.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Brainstorm Cell Therapeutics in a research report on Wednesday. They set a “hold” rating on the stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.